Press Release
Akebia Announces Initiation of Phase 2a Dose Range Finding Study of AKB-6548 for Anemia
Akebia Announces Initiation of Phase 2a Dose Range Finding Study of AKB-6548 for Anemia
June 23, 2011 at 12:00 AM EDT
Print Page
Email Page
Contact IR
Email Alerts
Tear Sheet
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax